Affibody molecules are small (6.5-kDa) affinity proteins based on a three-helix bundle
domain framework. Since their introduction 20 years ago as an alternative to antibodies for …

Affibody molecules can be used as tools for molecular recognition in diagnostic and
therapeutic applications. There are several preclinical studies reported on diagnostic and …

In the late 70's, the discovery of the restriction enzymes made possible the biological
production of functional proteins by recombinant DNA technologies, a fact that largely …

Radioisotopes of elements from all parts of the periodic table find both clinical and research
applications in radionuclide molecular imaging and therapy (nuclear medicine). This article …

The targeted delivery of radionuclides to tumours holds great promise for diagnosis and
treatment of malignant neoplasms. The development of scaffold proteins has significantly …

Despite some approvals of antibody-drug conjugates for cancer therapy, their clinical
success rate is unsatisfactory because of very small therapeutic windows, influenced by on …

Legumain, a lysosomal cysteine protease overexpressed in a variety of tumors, has been
considered a promising biomarker for various cancers. Precise detection of legumain activity …

The field of nuclear imaging and therapy is rapidly progressing with the development of
targeted radiopharmaceuticals that show rapid targeting and rapid clearance with minimal …

Purpose Human epidermal growth factor receptor-2 (HER2) overexpression is a predictor of
response to anti-HER2 therapy in breast and gastric cancer. Currently, HER2 status is …

The use of radiolabelled antibodies was proposed in 1970s for staging of malignant
tumours. Intensive research established chemistry for radiolabelling of proteins and …